Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report.

JTO clinical and research reports·2026
Same author

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Intensive care medicine·2026
Same author

DUSP1 is a Key Driver of Disease Persistence and Potential Therapeutic Target in Hairy Cell Leukemia.

Blood advances·2026
Same author

Cellular profile of hematopoietic stem cells mobilized by exercise versus G-CSF in healthy related donors.

European journal of applied physiology·2026
Same author

Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer.

Cancer cell·2026
Same author

Ex vivo modelling of human colorectal cancer liver metastasis by normothermic machine perfusion.

Molecular cancer·2025

Related Experiment Video

Updated: Jun 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Liver cancer: Targeted future options.

Andreas Pircher1, Michael Medinger, Joachim Drevs

  • 1Andreas Pircher, Department for Hematology and Oncology, Medical University Innsbruck, Anichstr. 35, Innsbruck 6020, Austria.

World Journal of Hepatology
|March 23, 2011
PubMed
Summary

Hepatocellular carcinoma (HCC) treatments are limited. This review explores novel anti-angiogenic and epidermal growth factor receptor (EGFR) therapies targeting tumor growth and vascularization in HCC.

Keywords:
AngiogenesisEpidermal growth factor receptorHepatocellular carcinomaTargeted therapyVascular endothelial growth factor

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Related Experiment Videos

Last Updated: Jun 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Area of Science:

  • Hepatocellular carcinoma (HCC) research
  • Molecular biology of cancer
  • Angiogenesis and cancer therapy

Background:

  • Hepatocellular carcinoma (HCC) presents a poor prognosis with limited systemic chemotherapy efficacy.
  • Vascular endothelial growth factor and epidermal growth factor receptor (EGFR) pathways are key molecular targets in HCC.
  • Angiogenesis, the formation of new blood vessels, is critical for solid tumor growth and HCC progression.

Purpose of the Study:

  • To review recent advances in understanding angiogenesis in HCC.
  • To summarize clinical trials of novel therapeutic strategies targeting angiogenesis and EGFR pathways in HCC.
  • To highlight the potential of anti-angiogenic therapies for HCC treatment.

Main Methods:

  • Literature review of basic science and clinical trial data.
  • Focus on therapeutic agents targeting angiogenesis and EGFR pathways.
  • Analysis of the role of angiogenesis in HCC development and progression.

Main Results:

  • Several anti-angiogenic agents, including monoclonal antibodies and tyrosine kinase inhibitors, are in clinical trials or approved for solid tumors.
  • HCC is a highly vascular tumor where angiogenesis plays a significant role.
  • Novel therapeutic approaches targeting angiogenesis and EGFR pathways show promise for HCC.

Conclusions:

  • Targeting angiogenesis and EGFR pathways represents a promising therapeutic strategy for Hepatocellular carcinoma (HCC).
  • Further research and clinical trials are essential to optimize these novel treatments for HCC patients.
  • Anti-angiogenic therapies offer a new modality for managing advanced HCC.